Finance entity
Every one of those 1 sits in a single category, earnings. Anthony Kirby is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Finance story that mention Hikma Pharmaceuticals, all published on August 10, 2026.
Last mentioned: Aug 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Anthony Kirby is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Finance story that mention Hikma Pharmaceuticals, all published on August 10, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Hikma Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Three London-listed mid-caps—Derwent London, Serco Group, and Hikma Pharmaceuticals—reported H1 results that collectively beat expectations and prompted guidance upgrades or reiteration. With rental growth at a decade high, defence spending flowing to outsourcers, and pharma injectables recovering, the results signal robust sectoral momentum despite geopolitical and macro risks.
Hikma Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
